(selected from a total of 59)
Fuleihan R, Ramesh N, Horner AA, Ahern D, Belshaw P, Alberg DG, Stanenkovic I, Harmon W, Geha RS. Cyclosporin A inhibits CD40 ligand expression in T-lymphocytes. J Clin Invest 93:1315-1320, 1994
Horner AA, Jabara H, Ramesh N, Geha RS. T-lymphocytes express CD40 ligand and induce isotype switching in B-lymphocytes. J Exp Med 181:1239-1244, 1995
Ramesh N, Horner AA, Ahern D, Geha RS. Bacterial superantigens induce the proliferation of resting receptor bearing cells. Immunol Invest 24:714-724, 1995
Horner AA, Ronaghy A, Cheng PM, Nguyen MD, Cho HJ, D. Broide, E. Raz. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 190:77-82, 1998.
Kobayashi H, Horner AA, Takabayashi K, Nguyen M-D, Huang E, Cinman N, Raz E. Immunostimulatory DNA prepriming: A novel approach for prolonged Th1-biased immunity. Cell Immunol 198:69-75, 1999.
Horner AA, Nguyen MD, Ronaghy A, Cinman N, Verbeek S, Raz E. DNA based vaccination reduces the risk of anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 106:349-356, 2000.
Childhood Asthma Management Program Research Group (Horner AA, Co-Principal Investigator, San Diego). Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054-1063, 2000.
Kobayashi H, Horner AA, Martin-Orozco E, Raz E. Pre-priming: A novel approach to DNA based vaccination and immunomodulation. Springer Sem Immunopathol 22:85-96, 2000.
Weiss ST, Horner A, Shapiro G, Sternberg AL for the Childhood Asthma Management Program Research Group (Horner AA, Co-Principal Investigator, San Diego). The prevalence of environmental exposure to perceived asthma triggers in children with mild to moderate asthma: Data from the Childhood Asthma Management Program Research Group (CAMP). J Allergy Clin Immunol 107:634-640, 2001.
Horner AA, Van Uden J, Zubeldia JM, Broide D, Raz E. DNA based immunotherapeutics for the treatment of allergic disease. Immunologic Rev 179:102-118, 2001.
Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol 108:417-423, 2001.
Horner AA, Datta SK, Takabayashi K, Belikov IM, Hayashi T, Cinman N, Nguyen M-D, Van Uden JH, Berzofsky JA, Richman DD, Raz E. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 167:1584-1591, 2001.
Nguyen MD, Takabayashi K, Horner AA. DNA based vaccination for the treatment of food allergy. Allergy 56 (Supp 67):127-130, 2001.
Cho HJ, Hayashi T, Datta SK, Takabayashi K, Van Uden JH, Horner A, Corr M, Raz E. IFN- promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168:4907-4913, 2002.
Horner AA, Takabayashi K, Beck L, Sharma B, Zubeldia J, Baird S, Tuck S, Libet L, Spiegelberg HL, Liu F‑T, Raz E. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 110:413-420, 2002.
Horner AA, Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: Two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 110:706-712, 2002.
Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol 170:3989-3905, 2003.
Horner AA, Raz E. Do microbes influence the pathogenesis of allergic diseases? Building the case for Toll-like receptor ligands. Curr Opin Immunol. 15: 614-619, 2003
Chisholm D, Libet L, Hayashi T, Horner AA. Airway exposures to peptidoglycan and immunostimulatory DNA have divergent immunologic consequences. J Allergy Clin Immunol, 113:448-454, 2004
Horner AA, Redecke V, Raz E: Toll-like receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 4:555-561, 2004.
Boasen J, Chisholm D, Lebet, L, Akira S, Horner AA. House dust extracts elicit toll like receptor dependent dendritic cell responses. J Allergy Clin Immunol, 116:185-191, 2005
Ng N, Lam D, Paulus P, Batzer G, Horner AA. House dust extracts have both Th2 adjuvant and tolerogenic activities, J Allergy Clin Immunol, 117:1974-1081, 2006.
Horner AA. Defining a role for mucosal immunity in the prevention and pathogenesis of respiratory allergic diseases. Curr Immunol. Rev. 2:157-167, 2006
Horner AA. Toll-like receptor ligands and Atopy: A coin with at least two sides. J All Clin Immunol. 117:1133-1140, 2006
Horner AA. Update on toll-like receptor ligands and allergy: Implications for immunotherapy. Current Allergy and Asthma Reports, 5:395-401, 2006.
Batzer G, Lam DP, Paulus P, Boasen J, Ng N, Horner AA. Using house dust extracts to understand the immunostimulatory activities of living environments. Immunobiology, 212:491-498, 2007 (PMCID: PMC1950943)
Tse K, Horner AA. Update on TLR directed therapies for human disease, Ann Rheum Disease, 66, Suppl 3:77-80, 2007
Tse K, Horner AA. Defining a role for ambient TLR ligand exposures in the genesis and prevention of allergic diseases, Sem Immunoppath, 30:53-62, 2008
Lam D, Ng N, Lee s, Batzer G, Horner AA. Airway house dust extract exposures modify allergen induced airway hypersensitivity responses by TLR4 dependent and independent pathways, J. Immunol, 181:2925-2932, 2008.
Tse K, Horner AA. Allergen tolerance versus the allergic march: the hygiene hypothesis revisited. Current Allergy and Asthma Reports, 6:475-483, 2008. |